Clinical trials: Erythropoietin
Anemia, Fatigue
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia.
- Conditions
- Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00258440
- Testing
- Weekly procrit dosing, Interval Dosing
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Sclerosis (Primary or Secondary Progressive Phase).
The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
In a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin (rhEPO) (48000 IU) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly for 12 weeks and bi-weekly for 12 weeks.
- Trial name
- EPO-ProgMS (NCT01144117)
- Testing
- Erythropoietin
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hypoxic Ischemic Encephalopathy
Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)
In this prospective trial the investigators plan to study the efficacy of erythropoietin as a therapeutic agent in neonates who suffer from brain injury following perinatal asphyxia.
- Trial name
- NCT00945789
- Testing
- Human recombinant erythropoietin, EEG and Brain MRI, Nitric oxide measurement in the blood
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Tanta University
Erythropoietin, Acute Kidney Injury
Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery
The purpose of the study is to evaluate kidney biomarkers and determine if there is a correlation between Erythropoietin (EPO) levels and acute kidney injury after cardiac surgery.
- Conditions
- Erythropoietin, Acute Kidney Injury, Renal Biomarker
- Trial name
- EPO (NCT01393418)
- Testing
- Cardiac Surgery
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Michigan
Anemia, Sepsis
Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial
Background Up to 66% of have anemia at the admission to the intensive care unit. This number increases to 95% after 72 hours of hospitalization in the intensive care unit due to illness and iatrogenic blood loss.
- Conditions
- Anemia, Sepsis, Septic Shock
- Trial name
- EpoAid (NCT06670963)
- Testing
- Iron, EPO, 0.9 % NaCl
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Piotr Czempik
Anemia
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
This observational study will evaluate the efficacy and safety of epoetin beta (NeoRecormon) in participants with symptomatic anemia and cancer receiving chemotherapy.
- Trial name
- NCT01809314
- Testing
- Epoetin beta
- Where
- 42 sites in Hungary
- Volunteers
- 1,167 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Anemia
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy
- Conditions
- Neoplasms, Anemia, Cancer
- Trial name
- NCT00386152
- Testing
- epoetin alfa, darbepoetin alfa
- Where
- 76 sites in United States
- Volunteers
- 235 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Chemotherapy
Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia
The purpose of this study was to test the effectiveness and safety of PROCRIT (Epoetin alfa) at a higher starting dose (60,000 Units) once per week, followed by a less frequent dose (60,000 Units every two weeks) in patients with…
- Trial name
- NCT00338299
- Testing
- Epoetin alfa
- Volunteers
- 51 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Myelodysplastic Syndromes
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
RATIONALE: Erythropoietin and colony-stimulating factors such as filgrastim stimulate the production of blood cells. It is not yet known whether erythropoietin with or without filgrastim is more effective than standard blood…
- Trial name
- NCT00003138
- Testing
- Erythropoietin, Filgrastim, Transfusion
- Where
- 28 sites in United States
- Volunteers
- 118 people
- Sponsor
- Eastern Cooperative Oncology Group
Renal Insufficiency, Chronic
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells.
- Trial name
- NCT03572647
- Testing
- Eritromax, Eprex
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Anemia, Kidney Disease, Chronic
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis
This comparative, open-label, multicenter, parallel-group study evaluated the effect of altitude on the dose requirements of Mircera (methoxy polyethylene glycol-epoetin beta) to achieve a target hemoglobin concentration of 11-12…
- Trial name
- ALTITUD (NCT01519947)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 7 sites in Mexico
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
Stroke
Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
The purpose of this study is: To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS-LED (NCT00938314)
- Testing
- human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Stem Cell Therapeutics Corp.
Anemia, Chronic Kidney Disease
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis, Chronic Kidney Disease 5D
- Trial name
- NCT07119372
- Testing
- BCD-131 (pegdarbepoetin beta), Mircera (methoxypolyethylene glycol-epoetin beta)
- Where
- 14 sites in Russia
- Volunteers
- 228 people
- Sponsor
- Biocad
Anemia
The Duration Study
The purpose of this study is to compare the efficacy of epoetin alfa (PROCRIT®) administered subcutaneously (sc) once every week (qw) vs. no epoetin alfa (PROCRIT®) treatment in patients with cancer who are anemic.
- Trial name
- NCT00210730
- Testing
- epoetin alfa
- Volunteers
- 2 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Neoplasms
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy
The purpose of this study is to evaluate the effectiveness and safety of Epoetin alfa administered at 60,000 Units every two weeks in cancer patients who are not receiving chemotherapy or radiation therapy.
- Trial name
- NCT00388336
- Testing
- Epoetin Alfa
- Volunteers
- 57 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Iron Deficiency Anemia
Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery
Study Design: Single-centre, block randomised, blinded, controlled, phase IIIb, parallel group pilot study. Primary Objective: To evaluate the effect of the administration of ferric carboxymaltose (Ferinject®) with or without…
- Trial name
- NCT00706667
- Testing
- Ferinject ®
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- University of Zurich
Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency
Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery
Pre-treatment of patients with erythropoietin subcutaneously and iron supplement intravenously, in order to create a clinical pathway to minimize transfusion of red blood cells in a selected group of cardiac patients with an…
- Trial name
- NCT02210949
- Testing
- Erythropoietin subcutaneously and Iron intravenously
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Anemia, Chronic Obstructive Pulmonary Disease
Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine the impact of erythropoietin treatment of anemia on exercise capacity of patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- ELAB (NCT00579046)
- Testing
- Darbepoetin alfa
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anemia
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia.
- Trial name
- NCT00090753
- Testing
- Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta
- Where
- 249 sites in United States, Australia and 25 more
- Volunteers
- 1,228 people
- Sponsor
- Hoffmann-La Roche
Anemia, Kidney Disease
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.
- Trial name
- NCT01235936
- Testing
- AKB-6548
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Akebia Therapeutics